What changed in Charles River Laboratories International, Inc.'s latest annual report
In the year ended 27 Dec 2025, Charles River Laboratories International, Inc.'s revenue fell 0.9% to USD 4.02bn, from USD 4.05bn; cash and cash equivalents rose 9.8% to USD 213.77m, from USD 194.61m; shareholders' equity fell 8.6% to USD 3.16bn, from USD 3.46bn.
Year ended 27 Dec 2025. Source: 10-K filed 18 Feb 2026, read it on SEC EDGAR.
USD 4.05bn to USD 4.02bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 4.05bn | 4.02bn | Down 0.9% |
| Net income | 22.20m | -144.34m | Not comparable |
| Total assets | 7.53bn | 7.14bn | Down 5.2% |
| Total liabilities | 4.02bn | 3.92bn | Down 2.4% |
| Cash and cash equivalents | 194.61m | 213.77m | Up 9.8% |
| Shareholders' equity | 3.46bn | 3.16bn | Down 8.6% |
Questions people ask
Did Charles River Laboratories International, Inc.'s revenue grow last year?
Revenue fell 0.9%, from USD 4.05bn to USD 4.02bn in the year ended 27 Dec 2025.
Is Charles River Laboratories International, Inc. profitable?
Not in its latest year: it reported a net loss of USD 144.34m in the year ended 27 Dec 2025. The year before: USD 22.20m.
How much cash and debt does Charles River Laboratories International, Inc. have?
At its latest year end (27 Dec 2025), Charles River Laboratories International, Inc. reported cash and cash equivalents of USD 213.77m.
Where do these numbers come from?
From Charles River Laboratories International, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Charles River Laboratories International, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc.Cash and cash equivalents up 16.3%
- Incyte CorporationNet income up 3845%
- Medpace Holdings, Inc.Shareholders' equity down 44.4%
- ICON plcNet income down 69%